Connect with Fyrn to explore how tailored market access and reimbursement strategies can support your product, portfolio, and long-term healthcare objectives.
Fyrn is a healthcare consultancy focused on supporting life sciences organisations in navigating complex market access and reimbursement environments. We work across pharmaceuticals, biotechnology, and medical devices to help clients achieve timely, sustainable patient access. Our approach combines strategic insight, evidence-based thinking, and deep understanding of payer and policy landscapes. By aligning clinical value, economic evidence, and stakeholder expectations, we enable informed decision-making across product lifecycles. Fyrn partners closely with clients to deliver practical, tailored solutions that reflect both global perspectives and local market realities.
Our mission is to enable sustainable patient access by delivering clear, evidence-led market access and reimbursement strategies grounded in integrity, collaboration, and long-term healthcare impact.
Early access, positioning and launch readiness
Evidenced aligned to payer and HTA expectations
Sustainable funding and adoption pathways
We provide strategic, evidence-led services supporting market access success across global healthcare systems.
We develop clear market access strategies enabling timely patient access across complex global healthcare systems.
We design sustainable pricing strategies aligned with value evidence, payer expectations, and long-term commercial objectives.
We support reimbursement planning to secure coverage decisions through evidence-driven engagement with payers and authorities.
We provide HTA strategy and submission support to strengthen value narratives and decision-making outcomes.
We craft compelling value propositions linking clinical outcomes, economic evidence, and stakeholder priorities across markets.
We support early and launch-phase planning to optimise access pathways and stakeholder engagement strategies.
We guide evidence strategies integrating clinical, economic, and real-world data to support access success.
Let’s collaborate to develop tailored market access and reimbursement strategies aligned with your product goals and healthcare priorities.
We combine strategic insight, evidence-led thinking, and practical expertise to deliver meaningful, sustainable market access outcomes.
Deep understanding of payer systems and access pathways across diverse global healthcare markets.
We align clinical, economic, and real-world evidence to support robust access decisions.
We work closely with clients as trusted partners throughout the entire product lifecycle.
Clear, actionable recommendations designed to deliver measurable access outcomes efficiently.
We follow a structured, evidence-led process to deliver clear, effective market access and reimbursement solutions.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since.
Lorem ipsum dolor sit amet conseur. Eu a pellentesque urna ut mattis sed ante turpis. Lectus sollicit.
Lorem ipsum dolor sit amet conseur. Eu a pellentesque urna ut mattis sed ante turpis. Lectus sollicit.
Lorem ipsum dolor sit amet conseur. Eu a pellentesque urna ut mattis sed ante turpis. Lectus sollicit.
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since.
Our clients value our strategic insight, collaborative approach, and ability to deliver impactful market access outcomes.
Find clear answers addressing our expertise, engagement models, and how we support successful healthcare access decisions.
We deliver strategic market access, reimbursement, pricing, evidence, and payer-focused consulting across global healthcare markets.
We work across pharmaceuticals, biotechnology, and medical devices, supporting products throughout development, launch, and lifecycle stages.
We support global strategies while addressing local payer, policy, and reimbursement requirements across diverse healthcare systems.
We combine strategic insight, evidence alignment, and stakeholder understanding to deliver clear, practical access solutions.
Yes, we provide HTA strategy, evidence development, and submission support aligned with payer expectations.
We advise on early access, evidence planning, and pricing considerations to support future reimbursement success.
We work collaboratively as strategic partners, integrating closely with client teams throughout project delivery.
Simply contact us to discuss your needs and explore tailored support aligned with your objectives.
Explore our expert perspectives on healthcare market access, reimbursement strategies, and evidence-based approaches shaping life sciences decision-making globally.
Understanding the hidden system dynamics shaping NHS reimbursement decisions. Strong clinical evidence and favourable cost-effectiveness models do not automatically translate into reimbursement. Many technologies fail not because the evidence is weak, but because it does not align with how payer systems actually make decisions.
How launch sequencing shapes global pricing power. Global pricing power is often determined long before negotiations begin. The order in which markets evaluate and reimburse a technology can quietly shape the pricing corridor available across multiple healthcare systems.
Why cost-effective technologies still struggle to diffuse. A technology can be cost-effective on paper yet still struggle to diffuse in practice. Adoption decisions are often shaped less by economic value and more by operational realities such as service capacity, workflow disruption and short-term budget pressures.
Reach out with questions or requests, and our team will respond promptly.
